BLAINE OSWALD: Open Payments
NPI 1285235341 · LEAVENWORTH, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,715 in 115 payments from 11 companies in 2025. Trend: 2023 $4,635 · 2024 $4,901 · 2025 $4,715
Speaker / faculty: $2,871Food & beverage: $1,451Travel & lodging: $167Consulting: $115Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $3,275 |
| Vanda Pharmaceuticals Inc. | 30 | $405 |
| Alkermes, Inc. | 19 | $239 |
| Teva Pharmaceuticals USA, Inc. | 10 | $227 |
| E.R. Squibb & Sons, L.L.C. | 10 | $161 |
| ABBVIE INC. | 19 | $155 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Janssen Pharmaceuticals, Inc | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Almatica Pharma LLC | 1 | $18 |
Products named: ABILIFY MAINTENA, HETLIOZ, ARISTADA, ABILIFY ASIMTUFII, REXULTI, VRAYLAR, SPRAVATO, COBENFY.
Industry payments across KS — which companies pay providers there.
